The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH/ISH 2016 | Novel treatments of AML in elderly patients
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY discusses new treatments for elderly acute myeloid leukemia (AML) patients outside of clinical trials. Although azacitidine and decitabine are not novel agents their application is new, and has somewhat replaced low-dose ara-C. However, azacitidine and decitabine produce low remission rates. According to Dr Roboz there is an increased interest in adding partners to the hypomethylating agent backbone to boast rates of complete remission. Furthermore, an increased number of transplants are being undertaken in elderly patients and if the efficacy of azacitidine and decitabine can be augmented, and thus higher remission rates, then older patients can proceed more quickly to transplant. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), in Glasgow, Scotland.
